Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

Algernon Pharmaceuticals Announces Completion of Enrollment in its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

GlobeNewswire February 4, 2022

Introducing Algernon Pharmaceuticals (CSE:AGN)

John Ballem  February 2, 2022

Algernon Pharmaceuticals (CSE:AGN) receives notice of allowance for Ifenprodil

Caroline Egan  January 28, 2022

Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent Application for Idiopathic Pulmonary Fibrosis

GlobeNewswire January 28, 2022

The Power Play by The Market Herald Releases Interviews with Algernon Pharmaceuticals, Newrange Gold, and Fokus Mining

Accesswire January 24, 2022

Algernon Pharmaceuticals (CSE:AGN) discloses novel salt patent strategy

John Ballem  January 24, 2022

Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual Property

GlobeNewswire January 24, 2022

The Power Play by The Market Herald Releases Interviews With Xali Gold, Falcon Gold, Psyched Wellness, Argentina Lithium, and Algernon Pharmaceuticals

Accesswire January 19, 2022

Algernon Pharmaceuticals (CSE:AGN) files for approval for Phase 1 DMT Human Stroke Study

John Ballem  January 19, 2022

Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study

GlobeNewswire January 19, 2022

The Power Play by The Market Herald Releases Interview with EarthRenew, Algernon Pharmaceuticals and Rockwell Medical

Accesswire January 14, 2022

Algernon Pharmaceuticals (CSE:AGN) receives positive feedback from the U.S. FDA for its Phase 2b Ifenprodil chronic cough study

John Ballem  January 14, 2022

Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study

GlobeNewswire January 14, 2022

Algernon Pharmaceuticals Issues Compensation Options

GlobeNewswire January 4, 2022

Algernon Pharmaceuticals (CSE:AGN) completes manufacturing of DMT and appoints UK stroke experts for phase 2 trials

John Ballem  December 8, 2021

Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2

GlobeNewswire December 8, 2021

Algernon Pharmaceuticals Projects Full Enrollment for Phase 2 IPF and Chronic Cough Trial

GlobeNewswire December 2, 2021

Algernon Pharmaceuticals (CSE:AGN) welcomes new CFO

John Ballem  November 30, 2021

Algernon Pharmaceuticals Announces New Chief Financial Officer

GlobeNewswire November 30, 2021

Top 5 Stories of the Week: Zoomd (TSXV:ZOMD), Highmark (TSXV:HMRK), FuelPositive (TSXV:NHHH), Max Resource (TSXV:MXR), and Algernon (CSE:AGN)

Julia Kennedy  November 26, 2021